WEE1i-ATRi combination therapy: a promising low-dose treatment for CCNE1-amplified gynecologic cancers

CCNE1 amplification is an oncogenic driver for many gynecologic cancers and is associated with poor patient outcomes. In this issue, Xu et al.(1) identify a combination therapy that is responsive to high CCNE1-copy number ovarian and endometrial cancers using PDX models.

Detalles Bibliográficos
Autores principales: Goehring, Liana, Huang, Tony T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Preview
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8484682/
https://www.ncbi.nlm.nih.gov/pubmed/34622238
http://dx.doi.org/10.1016/j.xcrm.2021.100402
Descripción
Sumario:CCNE1 amplification is an oncogenic driver for many gynecologic cancers and is associated with poor patient outcomes. In this issue, Xu et al.(1) identify a combination therapy that is responsive to high CCNE1-copy number ovarian and endometrial cancers using PDX models.

Ejemplares similares